Abstract
The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Letters in Drug Design & Discovery
Title:In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Volume: 9 Issue: 4
Author(s): Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala
Affiliation:
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Abstract: The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Export Options
About this article
Cite this article as:
Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala , In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799859927
DOI https://dx.doi.org/10.2174/157018012799859927 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tankyrase Inhibitors as Therapeutic Targets for Cancer
Current Topics in Medicinal Chemistry Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Current Topics in Medicinal Chemistry Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry From Gut Homeostasis to Cancer
Current Molecular Medicine Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Screening and Identification of Differentially Expressed Genes Between Diabetic Nephropathy Glomerular and Normal Glomerular via Bioinformatics Technology
Combinatorial Chemistry & High Throughput Screening Applicability and Approaches of (Meth) Acrylate Copolymers (Eudragits) in Novel Drug Delivery Systems
Current Drug Therapy Cancer Prevention by Dietary Bioactive Components that Target the Immune Response
Current Cancer Drug Targets Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Therapeutic Proteins: A to Z
Protein & Peptide Letters PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition
Current Protein & Peptide Science NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Chemistry, Stability and Bioavailability of Resveratrol
Medicinal Chemistry Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry